101. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
- Author
-
Guo ZQ, Zheng T, Chen B, Luo C, Ouyang S, Gong S, Li J, Mao LL, Lian F, Yang Y, Huang Y, Li L, Lu J, Zhang B, Zhou L, Ding H, Gao Z, Zhou L, Li G, Zhou R, Chen K, Liu J, Wen Y, Gong L, Ke Y, Yang SD, Qiu XB, Zhang N, Ren J, Zhong D, Yang CG, Liu J, and Jiang H
- Subjects
- Animals, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell metabolism, Female, Humans, Kidney Neoplasms genetics, Kidney Neoplasms metabolism, Male, Mice, Inbred BALB C, Mice, Inbred ICR, Molecular Targeted Therapy, Nuclear Proteins genetics, Nuclear Proteins metabolism, Repressor Proteins genetics, Repressor Proteins metabolism, Signal Transduction, Ubiquitin-Protein Ligases metabolism, Xenograft Model Antitumor Assays, Carcinoma, Renal Cell drug therapy, Kidney Neoplasms drug therapy, Nuclear Proteins antagonists & inhibitors, Repressor Proteins antagonists & inhibitors, Small Molecule Libraries pharmacology
- Abstract
In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC), speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may induce proliferation and promote kidney tumorigenesis. In normal cells, however, SPOP is located in the nucleus and induces apoptosis. Here we show that a structure-based design and subsequent hit optimization yield small molecules that can inhibit the SPOP-substrate protein interaction and can suppress oncogenic SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally affect the viability of other cells in which SPOP is not accumulated in the cytoplasm. Our findings validate the SPOP-substrate protein interaction as an attractive target specific to ccRCC that may yield novel drug discovery efforts., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF